Business Wire

THALES

Share
New Era of Remote Working Calls for Modern Security Mindset, Finds Thales Global Survey of IT Leaders

COVID-19 quickly ushered in the era of remote work, introducing new risks that IT professionals are struggling to manage with existing security tools, according to a new Thales study. Six in 10 respondents said traditional security tools such as VPNs are still the primary vehicle for employees accessing applications remotely -- likely the reason why almost half (44%) were not confident that their access security systems could scale effectively to secure remote work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005014/en/

These are among the key insights from the 2021 Thales Access Management Index , a global survey of 2,600 IT decision makers, commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, to better understand the new security risks and challenges caused by the rise of remote working and cloud transformation caused by the COVID-19 pandemic.

Last year saw a surge in cybercrime exploiting the various aspects of the COVID-19 pandemic and the shift to remote work, with ransomware attacks soaring by 150%.1 The Thales survey found the pandemic’s effects have had a significant impact on security infrastructure, particularly on access management and authentication frameworks, pushing organisations to adopt modern security strategies like Zero Trust to support the demands of a more mobile and remote workforce.

Era of Remote Working – Concerns Catalyse Change

According to the index, respondents have many different systems deployed for remote access. When asked about the technologies that were in place, VPN was the most common, with 60% of IT professionals identifying the capability. Virtual Desktop Infrastructure, cloud-based access and Zero Trust network access/software defined perimeter (ZTNA/SDP) closely followed. However, when asked what new access technologies respondents were planning to deploy due to the pandemic, nearly half (44%) indicated ZTNA/SDP was the top technology choice.

Thales also explored respondents’ plans to move beyond traditional VPN environments, and found that nearly 40% expect to replace their VPN with ZTNA/SDP, while 38% expect to move to a Multi-Factor Authentication (MFA) solution. This confirms the need for more modern, sophisticated authentication capabilities is driving change in many organisations and is perceived as a key enabler of Zero Trust security.

“Seemingly overnight, remote access went from being an exception to the default working model for a large swath of employees. As a result, businesses are navigating a volatile and complex world, and adopting a Zero Trust model of cybersecurity will enable them to continue to conduct operations safely amidst the uncertainty,” said Francois Lasnier, vice president of Access Management solutions at Thales . “One of the core barrier businesses face when starting their Zero Trust journey is the balance between locking down access without interrupting workflow. People require access to sensitive data in order to work and collaborate and businesses leaders will need to ensure that a drop in productivity doesn’t become an unwanted side effect. The research shows that IT professionals increasingly see access management and modern authentication capabilities as key component in achieving a Zero Trust model.”

Room to Grow with Zero Trust

The Thales report found that Zero Trust models are the solution of choice for respondents seeking to improve access environments, yet many are still in the early stage of adoption.

According to the research, less than a third (30%) of the respondents claim to have a formal strategy and have actively embraced a Zero Trust policy. Additionally, almost half (45%) are either planning, researching or considering a Zero Trust strategy. Surprisingly, less than a third (32%) of the respondents indicated that Zero Trust shapes their cloud security strategy to a great extent.

Access Security Needs to Adapt to Deal with Dynamic Workplaces

A silver lining of the pandemic-driven rush to remote working is the acceleration of improved approaches to access security. Thales found that 55% of respondents currently have adopted two-factor authentication within their organisations. Regionally, there was notable variation, with the UK leading (64%), followed by the U.S. (62%), APAC (52%) and LATAM (40%). These varying degrees of adoption may be due to the level at which better access management is prioritised in security investments.

Yet, despite the well-known limitations of passwords, investment in MFA still trails other security tools like firewalls, endpoint security, SIEM and email security. Remote access users are still the main use case for MFA adoption (71%). One-third of respondents that have adopted MFA use more than three different authentication tools, signaling the need for a more unified approach to access management in the future.

“Security tools and approaches need to adapt to better support the era of remote working,” said Eric Hanselman, chief analyst at 451 Research, part of S&P Global Market Intelligence . “The shift towards a Zero Trust model, along with increasing use of modern authentication technologies, like adaptive and multifactor authentication (MFA), will improve organisations’ security posture. This will be an exciting space to watch as businesses continue to deal with dynamic workplace environments.” 2

Thales and 451 Research will discuss the global findings in more detail during its upcoming Trusted Access Summit on 5 October 2021. To join, please visit the registration page .

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

1 Group-IB Ransomware Uncovered 2020-2021
2 Quote from Thales 2021 Global Access Management Index

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye